LETROVIB 2.5LETROZOLE 2.5mg. IP

Letrovib 2.5 tablets contain Letrozole 2.5 mg, a hormone therapy used in postmenopausal women with certain breast cancers. Main uses: adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer; extended adjuvant treatment of postmenopausal women with early breast cancer who have already had 5 years of adjuvant tamoxifen therapy; first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer; second-line treatment of postmenopausal women with advanced breast cancer that has progressed after antiestrogen therapy.

Common side effects of Letrovib 2.5 Tablet include hot flashes; joint pain; flushing; weakness or lack of energy; swelling in the hands, arms, legs or feet; headache. Get medical help at once if you notice decrease in bone mineral density, which can raise the chance of fractures; increase in total blood cholesterol levels; severe allergic reaction to letrozole or any of the excipients.

Each Letrovib 2.5 tablet contains Letrozole 2.5 mg. The right dose and how long to take it depend on the condition, age and other medicines, so use Letrovib 2.5 Tablet only as your doctor advises.

The MRP of Letrovib 2.5 Tablet is ₹157.6 for a pack of 10x5 (Blister). For chemists and distributors, the PTR is ₹120.08 and the PTS is ₹108.07.

Each Letrovib 2.5 tablet contains Letrozole 2.5 mg. It comes in a pack of 10x5 (Blister).

In postmenopausal women, oestrogen is produced mainly when the aromatase enzyme converts adrenal androgens into oestrone and oestradiol. Letrozole blocks this enzyme, so the amount of oestrogen made in the body and in the breast tissue falls. Some breast cancers grow with the help of oestrogen, and lowering oestrogen levels helps to slow the growth of these hormone-sensitive tumours.

Must not be used in pregnancy, as letrozole can cause harm to the unborn baby. Must not be used by anyone with known hypersensitivity to letrozole or to any of the excipients. Females of reproductive potential must have a pregnancy test before starting treatment and use effective contraception during treatment. Check with a doctor first if you have osteoporosis or low bone mineral density, as bone density may fall further during treatment. Check with a doctor first if you have high cholesterol, as cholesterol levels may rise and monitoring may be needed.

Letrovib 2.5 Tablet is a brand of Vibcare Pharma, sold through its Genvimax division. It is available for PCD pharma franchise and distribution in India; use the Send Enquiry or WhatsApp button on this page to ask about availability and terms.